Literature DB >> 22715200

Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.

D H Nieman1, A L Sutterland, J Otten, H E Becker, M L Drent, M van der Gaag, M Birchwood, L de Haan.   

Abstract

The patient in this case report had two severe medical conditions that require oppositional treatment: prolactinoma and psychosis. A prolactinoma is a benign tumour of the pituitary gland that produces prolactin. Dopamine agonist medication is the first-line treatment in patients with prolactinoma. The psychotic symptoms started after a dosage increase of a dopamine D2-receptor agonist. Several antipsychotic medications were tried with and without the dopamine D2-receptor agonist, but severe command hallucinations remained. Cognitive behavioural therapy (CBT) was added which reduced the impact of the hallucinations to a great extent, indicating that CBT can have an additional positive effect in prolactinoma patients with psychosis that shows incomplete recovery after antipsychotic medication. Future research should be aimed at the severe and prolonged side effects of dopamine agonists in the treatment of prolactinoma patients with multiple risk factors for a psychotic decompensation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22715200      PMCID: PMC3062833          DOI: 10.1136/bcr.07.2010.3185

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  The environment and schizophrenia: the role of cannabis use.

Authors:  Cécile Henquet; Robin Murray; Don Linszen; Jim van Os
Journal:  Schizophr Bull       Date:  2005-06-23       Impact factor: 9.306

2.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Authors:  Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

3.  Acting on voices: Omnipotence, sources of threat, and safety-seeking behaviours.

Authors:  David Hacker; Max Birchwood; Jeremy Tudway; Alan Meaden; Catherine Amphlett
Journal:  Br J Clin Psychol       Date:  2007-10-23

4.  Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.

Authors:  Bradley Freeman; Woodburne Levy; Jack M Gorman
Journal:  J Psychiatr Pract       Date:  2007-03       Impact factor: 1.325

Review 5.  Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.

Authors:  Sarah Konopelska; Marcus Quinkler; Christian J Strasburger; Manfred Ventz
Journal:  J Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.153

6.  Competitive memory training (COMET) for treating low self-esteem in patients with eating disorders: A randomized clinical trial.

Authors:  Kees Korrelboom; Martie de Jong; Irma Huijbrechts; Peter Daansen
Journal:  J Consult Clin Psychol       Date:  2009-10

7.  Interpersonal and role-related schema influence the relationship with the dominant 'voice' in schizophrenia: a comparison of three models.

Authors:  Max Birchwood; Paul Gilbert; Jean Gilbert; Peter Trower; Alan Meaden; Justin Hay; Eleanor Murray; Jeremy N V Miles
Journal:  Psychol Med       Date:  2004-11       Impact factor: 7.723

8.  Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra.

Authors:  E D French; K Dillon; X Wu
Journal:  Neuroreport       Date:  1997-02-10       Impact factor: 1.837

9.  Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS).

Authors:  G Haddock; J McCarron; N Tarrier; E B Faragher
Journal:  Psychol Med       Date:  1999-07       Impact factor: 7.723

Review 10.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

View more
  1 in total

Review 1.  Treatment of Prolactinoma.

Authors:  Warrick J Inder; Christina Jang
Journal:  Medicina (Kaunas)       Date:  2022-08-13       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.